University of Michigan-Ann Arbor · BiologyAcute Leukemia Therapeutics Lab
Jolanta Grembecka · Ann Arbor, Michigan
Research Focus
Dr. Jolanta Grembecka's lab at the University of Michigan focuses on developing new therapies for acute leukemia, particularly targeting proteins involved in the disease's development. Their research aims to create small molecule inhibitors that can disrupt key interactions, helping to halt the progression of leukemias characterized by specific genetic mutations. This work is vital in improving survival rates for leukemia patients who currently have limited treatment options.
acute leukemiameninASH1LHOX genesdrug developmentsmall molecule inhibitorsleukemia resistance
Research Aims
5AIM 01Develop next-generation small molecule inhibitors targeting the menin-MLL1 interaction.
AIM 02Optimize ASH1L inhibitors for increased potency and specificity.
AIM 03Evaluate drug efficacy in advanced leukemia models with resistant mutations.
AIM 04Investigate optimal drug combinations for enhanced therapeutic outcomes.
AIM 05Assess the mechanism of action of new inhibitors in patient-derived samples.
Skills the Lab Values
medicinal chemistryprotein-protein interaction studiescell culturein vitro drug testingmouse modelsbiochemical assayspharmacokineticsxenograft modelsH3K36 methylation analysis
Output against the department
Publications260top 23% of dept.237th of 1,033
this lab
most publishedleast published
Citations6.2kbottom 44% of dept.575th of 1,033
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.